KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) soaring 30% in early morning trading, adding to their 20% rise after Friday’s news that the company appointed Martin Shkreli as …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the promotion of Richard Wright, Ph.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2015.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) received another set of praises from analysts at Roth Capital, in addition to analysts at Cowen and Brean Capital.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it is offering 7.
Shares of Celldex Therapeutics (NASDAQ: CLDX) shot up about 17.5% in trading on February 23rd following the company’s announcement that it was granted FDA approval …
Celldex Therapeutics, Inc. (Nasdaq:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2014.
